drugset / Trial / NCT03628677
A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase 1, multicenter, open-label, dose-escalation study to evaluate the safety, tolerability, PK, PD, and clinical activity of domvanalimab (AB154) as monotherapy and in combination with zimberelimab (AB122) in participants with advanced solid malignancies.
Timeline
- Start
- 2018-09-12
- Primary completion
- 2025-01-23
- Completion
- 2025-01-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Domvanalimab | Monoclonal antibody | — | — |
| Subject | Zimberelimab | Monoclonal antibody | — | — |